Novel inhibitor of p38 MAP kinase as an anti-TNF-α drug: Discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent

Journal of Medicinal Chemistry

Volumn 48, Issue 19, 2005, Pages 5966-5979

  Miwatashi, Seiji ^a   Arikawa, Yasuyoshi ^a   Kotani, Etsuo ^a   Miyamoto, Maki ^a   Naruo, Ken Ichi ^a   Kimura, Hiroyuki ^a   Tanaka, Toshimasa ^a   Asahi, Satoru ^a   Ohkawa, Shigenori ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHENYL 5 PYRIDYL 1,3 THIAZOLE DERIVATIVE; 4 PYRIDYL NITROGEN; ANTIRHEUMATIC AGENT; HEME DERIVATIVE; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N [4 [2 ETHYL 4 (3 METHYLPHENYL) 1,3 THIAZOL 5 YL] 2 PYRIDYL]BENZAMIDE; SYNAPTOPHYSIN; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CHRONIC INFLAMMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG BIOAVAILABILITY; DRUG POTENCY; ENTERITIS; ENZYME INHIBITION; IN VITRO STUDY; INFLAMMATION; INHIBITION KINETICS; MOUSE; NONHUMAN; RAT; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION;

ADMINISTRATION, ORAL; ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; BENZAMIDES; BIOLOGICAL AVAILABILITY; CELL LINE; CELL LINE, TUMOR; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; ISOENZYMES; MALE; MICE; MICROSOMES; MODELS, MOLECULAR; MONOCYTES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RATS; RATS, INBRED LEW; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 24944521495     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050165o     Document Type: Article

References (23)

1. Elliott, M. J.; Maini, R. N.; Feldmann, M.; Kalden, J. R.; Antoni, C.; Smolen, J. S.; Leeb, B.; Breedveld, F. C.; Macfarlane, J. D.; Bijl, H.; Woody, J. N. Randomised Double-Blind Comparison of Chimeric Monoclonal Antibody to Tumour Necrosis Factor α (cA2) versus Placebo in Rheumatoid Arthritis. Lancet 1994, 344, 1105-1110.
2. Rankin, E. C.; Choy, E. H.; Kassimos, D.; Kingsley, G. H.; Sopwith, A. M.; Isenberg, D. A.; Panayi, G. S. The Therapeutic Effects of an Engineered Human Antitumor Necrosis Factor Alpha Antibody (CDP571) in Rheumatoid Arthritis. Br. J. Rheumatol. 1995, 34, 334-342.
3. Van Dulleman, H. M.; Van Deventer, S. J. H.; Hommes, D. W.; Bijl, H. A.; Jansen, J.; Tytget, G. N.; Woody, J. Treatment of Crohn's Disease with Antitumor Necrosis Factor Chimeric Monoclonal Antibody (cA2). Gastroenterology 1995, 109, 129-135.
4. Moreland, L. W.; Baumgartner, S. W.; Schiff, M. H.; Tindall, E. A.; Fleischmann, R. M.; Weaver, A. L.; Ettlinger, R. E.; Cohen, S.; Koopman, W. J.; Mohler, K.; Widmer, M. B.; Blosch, C. M. Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)-Fc Fusion Protein. N. Engl. J. Med. 1997, 337, 141-147.
5. Bresnihan, B. The Prospect of Treating Rheumatoid Arthritis with Recombinant Human Interleukin-1 Receptor Antagonist. BioDrugs 2001, 15, 87-97.
6. Lee, J. C.; Laydon, J. T.; McDonnell, P. C.; Gallagher, T. F.; Kumar, S.; Green, D.; McNulty, D.; Blumenthal, M. J.; Keys, J. R.; Landvatter, S. W.; Strickler, J. E.; McLaughlin, M. M.; Siemens, I. R.; Fisher, S. M.; Livi, G. P.; White, J. R.; Adams, J. L.; Young, P. R. A Protein Kinase Involved in the Regulation of Inflammatory Cytokine Biosynthesis. Nature 1994, 372, 739-746.
7. Dumas, J. Protein Kinase Inhibitors from the Urea Class. Curr. Opin. Drug Discovery Dev. 2002, 5, 718-727.
8. Miwatashi, S.; Arikawa, Y.; Naruo, K.; Igaki, K.; Watanabe, Y.; Kimura, H.; Kawamoto, T.; Ohkawa, S. Synthesis and Biological Activities of 4-Phenyl-5-pyridyl-l,3-thiazole Derivatives as p38 MAP Kinase Inhibitors. Chem. Pharm. Bull. 2005,53, 410-418.
9. Steven, A. W.; Erin, G. S.; Kenneth, E. T.; Danny, D. S.; Kenneth, R. K.; Paul, B. W. The Human CYP3A Subfamily: Practical Considerations. Drug Metab. Rev. 2000, 32, 339-361.
10. Testa, B.; Jenner, P. Inhibitors of Cytochrome P-450s and Their Mechanism of Action. Drug Metab. Rev. 1981, 12, 1-117.
11. Jerry, L. A.; Jeffrey, C. B.; Shouki, K.; Peter, D. G.; Edward, F. W.; Ralph, H.; Margaret, S.; John, C. L.; Andrew, A.; Don, E. G.; Timothy, F. G. Pyrimidinylimidazole Inhibitors of CSBP/p38 Kinase Demonstrating Decreased Inhibition of Hepatic Cytochrome P450 Enzymes. Bioorg. Med. Chem. Lett. 1998, 8, 3111-3116.
12. Collis A. J.; Foster M. L.; Halley F.; Maslen C.; McLay I. M.; Page K. M.; Redford E. J.; Souness J. E.; Wilsher N. E. RPR203494 a Pyrimidine Analogue of the p38 Inhibitor RPR200765A with an Improved in Vitro Potency. Bioorg. Med. Chem. Lett. 2001, 11, 693-696.
13. Laufer, S. A.; Wagner, G. K.; Kotschenreuther, D. A.; Albrecht, W.; Novel Substituted Pyridinyl Imidazoles as Potent Anticytokine Agents with Low Activity against Hepatic Cytochrome P450 Enzymes. J. Med. Chem. 2003, 46, 3230-3244.
14. Wang, Z.; Canagarajah, B. J.; Boehm, J. C.; Kassisà, S.; Cobb, M. H.; Young, P. R.; Abdel-Meguid, S.; Adams, J. L. Goldsmith, E. J. Structural Basis of Inhibitor Selectivity in MAP Kinases. Structure 1998, 6, 1117-1128. (Protein Data Bank Code 1A9U).
15. Dresser, G. K.; Spence, J. D.; Bailey, D. G. Pharmacokinetic- pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin. Pharmacokinet. 2000, 38, 41-57.
16. Liverton, N. J.; Butcher, J. W.; Claiborne, C. F.; Claremon, D. A.; Libby, B. E.; Nguyen, K. T.; Pitzenberger, S. M.; Selnick, H. G.; Smith, G. R.; Tebben, A.; Vacca, J. P.; Varga, S. L.; Agarwal, L.; Dancheck, K.; Forsyth, A. J.; Fletcher, D. S.; Frantz, B.; Hanlon, W. A.; Harper, C. F.; Hofsess, S. J.; Kostura, M.; Lin, J.; Luell, S.; O'Neill, E. A.; Orevillo, C. J.; Pang, M.; Parsons, J.; Rolando, A.; Sahly, Y.; Visco, D. M.; O'Keefe, S. J. Design and Synthesis of Potent, Selective, and Orally Bioavailable Tetra-substituted Imidazole Inhibitors of p38 Mitogen-Activated Protein Kinase. J. Med. Chem. 1999, 42, 2180-2190.
17. Roe, A.; Cheek, P. H.; Hawkins, G. F. The Synthesis of 2-Fluoro-4-and 2-Fluoro-6-pyridinecarboxylic Acid and Derivatives. J. Am. Chem. Soc. 1949, 71, 4152-4153.
18. Anderson, W. K.; Dean, D. C.; Endo, T. Synthesis, Chemistry, and Antineoplastic Activity of a-Halopyridinium Salts: Potential Pyridone Prodrugs of Acylated Vinylogous Carbinolamine Tumor Inhibitors. J. Med. Chem. 1990, 33, 1667-1675.
19. Hands, D.; Bishop, B.; Cameron, M.; Edwards, J. S.; Cottrell, I. F.; Wright, S. H. B. A Convenient Method for the Preparation of 5-, 6- and 7-Azaindoles and Their Derivatives. Synthesis 1996, 877-882.
20. Ihle, N. C.; Krause, A. E. Preparation of 4-Alkyl-2-[N-(tert- butoxycarbonyl)aminolpyridines by Alkylation, Nucleophilic Addition, and Acylation of 2-[N-(terf-Butoxycarbonyl)amino]-4-picoline. J. Org. Chem. 1996, 61, 4810-4811.
21. Han, J.; Richter, B.; Li, Z.; Kravchenko, V.; Ulevitch, R. J. Molecular Cloning of Human p38 MAP Kinase. Biochim. Biophys. Acta 1995, 1265, 224-227.
22. Derijard, B.; Raingeaud, J.; Barrett, T.; Wu, I. H.; Han, J.; Ulevitch, R. J.; Davis, R. J. Independent Human MAP-kinase Signal Transduction Pathways Defined by MEK and MKK Isoforms. Science 1995, 267, 682-685.
23. Stein, B.; Brady, H.; Yang, M. X.; Young, D. B.; Barbosa, M. S. Cloning and Characterization of MEK6, a Novel Member of the Mitogen-activated Protein Kinase Kinase Cascade. J. Biol. Chem. 1996, 271, 11427-11433.